Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Bellerophon Ther Com (BLPH)

Bellerophon Ther Com (BLPH)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 32,917
  • Shares Outstanding, K 68,907
  • Annual Sales, $ 0 K
  • Annual Income, $ 2,810 K
  • 60-Month Beta -0.04
  • Price/Sales N/A
  • Price/Cash Flow 9.98
  • Price/Book 2.76
  • Price/Earnings ttm 4.18
  • Earnings Per Share ttm -0.07
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 11/06/19
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/19
See More
  • Average Estimate -0.08
  • Number of Estimates 2
  • High Estimate -0.06
  • Low Estimate -0.09
  • Prior Year 0.18
  • Growth Rate Est. (year over year) -144.44%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.42 +15.59%
on 09/27/19
0.63 -21.94%
on 09/18/19
-0.11 (-18.52%)
since 09/17/19
3-Month
0.42 +15.59%
on 09/27/19
0.75 -34.95%
on 07/19/19
-0.16 (-24.36%)
since 07/17/19
52-Week
0.42 +15.59%
on 09/27/19
1.22 -60.01%
on 01/11/19
-0.53 (-52.17%)
since 10/17/18

Most Recent Stories

More News
Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting

Results to be Presented in Late-Breaking Abstract as an Oral Presentation

BLPH : 0.49 (+2.14%)
Bellerophon Receives Orphan Drug Designation for Nitric Oxide in the Treatment of Idiopathic Pulmonary Fibrosis

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, announced today the U.S. Food and Drug Administration (FDA) has granted Orphan...

BLPH : 0.49 (+2.14%)
Bellerophon to Present at the H.C. Wainwright 21st Annual Global Investment Conference

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, announced today that Fabian Tenenbaum, Chief Executive Officer, will present a...

BLPH : 0.49 (+2.14%)
Bellerophon Therapeutics: 2Q Earnings Snapshot

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Thursday reported a loss of $4.1 million in its second quarter.

BLPH : 0.49 (+2.14%)
Bellerophon Provides Business Update and Reports Second Quarter 2019 Financial Results

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the three and...

BLPH : 0.49 (+2.14%)
Bellerophon Completes Enrollment in Cohort 2 of Ongoing Phase 2/3 Study of INOpulse(R) for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) ("Bellerophon" or the "Company"), a clinical-stage biotherapeutics company, today announced that it has completed enrollment for Cohort 2 of its ongoing Phase...

BLPH : 0.49 (+2.14%)
INOpulse Drug Overview & Product Profiles 2016-2025

The "INOpulse" report has been added to ResearchAndMarkets.com's offering.

BLPH : 0.49 (+2.14%)
INOpulse (Bellerophon Therapeutics Overview: A Drug-Device Combination Being Developed to Deliver a Continuous, Pulsed Dose of Nitric Oxide Via Intranasal Inhalation - ResearchAndMarkets.com

The "INOpulse" report has been added to ResearchAndMarkets.com's offering.

BLPH : 0.49 (+2.14%)
Socati Board of Director Appointments Bring Significant Leadership Experience to Accelerate Company Growth, Advance Hemp Industry

--Appointments follow acquisition of major processing facility, enabling large-scale production, product purity and quality of broad-spectrum hemp extracts

PG : 116.63 (-0.77%)
OC : 62.76 (+0.29%)
AMGN : 203.56 (+0.17%)
NVS : 87.23 (+0.26%)
BLPH : 0.49 (+2.14%)
AVTR : 13.96 (+0.14%)
ORCL : 55.06 (-1.47%)
Bellerophon Therapeutics: 1Q Earnings Snapshot

WARREN, N.J. (AP) _ Bellerophon Therapeutics Inc. (BLPH) on Thursday reported a first-quarter loss of $795,000, after reporting a profit in the same period a year earlier.

BLPH : 0.49 (+2.14%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Average short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More Share

Trade BLPH with:

Business Summary

Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton,...

See More

Key Turning Points

2nd Resistance Point 0.52
1st Resistance Point 0.50
Last Price 0.49
1st Support Level 0.47
2nd Support Level 0.45

See More

52-Week High 1.22
Fibonacci 61.8% 0.92
Fibonacci 50% 0.82
Fibonacci 38.2% 0.73
Last Price 0.49
52-Week Low 0.42

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar